THE PHARMACOKINETICS OF N-[C-14-FORMYL]-LEUROSINE IN HUMANS

dc.contributor.author	Erdélyi-Tóth, V
dc.contributor.author	Csetényi, J
dc.contributor.author	Kanyár, B
dc.contributor.author	Kerpel-Fronius, Sándor
dc.contributor.author	Eckhardt, S
dc.date.accessioned	2022-09-01T06:49:15Z
dc.date.available	2022-09-01T06:49:15Z
dc.date.issued	1981
dc.identifier	0019378116
dc.identifier.citation	journalVolume=17;journalIssueNumber=3;journalTitle=EUROPEAN JOURNAL OF CANCER;pagerange=329-335;journalAbbreviatedTitle=EUR J CANCER;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/8082
dc.description.abstract	N-Formyl-leurosine labeled with 14C in the formyl group was administered to six patients with malignant disease, and the pharmacokinetic behavior of the drug was determined. Chromatographic studies on plasma showed the presence of unchanged drug and 7 metabolites. No metabolites were found in the urine. The plasma decay curve of the unchanged drug was biphasic with half-life values of t1 2α = 18.6 min and t1 2β = 4.28 hr. Within 72 hr only 30-40% of the radioactivity could be recovered in urine and feces in 5 patients. One patient consumed laxatives during the treatment. In this case 95% of the 14C-dose was recovered. The contribution made by fecal elimination was 80%. © 1981.
dc.format.extent	329-335
dc.relation.ispartof	urn:issn:0959-8049
dc.title	THE PHARMACOKINETICS OF N-[C-14-FORMYL]-LEUROSINE IN HUMANS
dc.type	Journal Article
dc.date.updated	2019-12-05T12:27:14Z
dc.language.rfc3066	en
dc.rights.holder	NULL
dc.identifier.mtmt	2226498
dc.identifier.wos	A1981LC62200008
dc.identifier.pubmed	7262170
dc.contributor.institution	Országos Onkológiai Intézet
dc.contributor.institution	Farmakológiai és Farmakoterápiás Intézet